Virus-based immunotherapy of cancer: What do we know and where are we going?

APMIS

Volumn 115, Issue 11, 2007, Pages 1177-1193

  Sørensen, Maria Rathmann ^a   Thomsen, Allan Randrup ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer immunotherapy; Immunosubversion; T cells; Virus based vaccination

Indexed keywords

CANCER VACCINE; CD134 ANTIGEN; GLUCOCORTICOID; INTERLEUKIN 10; PD 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MACROPHAGE; NEOPLASM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERFERONS; INTERLEUKINS; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; VIRAL VACCINES;

EID: 37349034229     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0643.2007.00802.x     Document Type: Review

References (104)

1. Schreurs MWJ, Eggert AAO, de Boer AJ, Vissers JLM, van Hall T, Offringa R, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000 60 : 6995 7001.
2. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006 58 : 931 47.
3. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003 3 : 431 7.
4. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006 29 : 233 40.
5. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006 213 : 131 45.
6. McCluskie MJ, Weeratna RD. Novel Adjuvant Systems. Curr Drug Targets Infect Disord 2001 1 : 263 71.
7. Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000 74 : 11 25.
8. Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004 78 : 5966 72.
9. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004 10 : 616 29.
10. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999 29 : 964 72.
11. Hensley SE, Giles-Davis W, McCoy KC, Weninger W, Ertl HC. Dendritic cell maturation, but Not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 2005 175 : 6032 41.
12. Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K, et al. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 2004 78 : 11152 60.
13. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991 65 : 305 17.
14. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006 12 : 2326S 30S.
15. Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G, et al. CD8(+) T-cell tolerance can be broken by an adenoviral vaccine while CD4(+) T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006 63 : 35 41.
16. Elia L, Aurisicchio L, Facciabene A, Giannetti P, Ciliberto G, La Monica N, et al. CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther 2006.
17. Steinaa L, Rasmussen PB, Wegener AM, Sonderbye L, Leach DR, Rygaard J, et al. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol 2005 175 : 329 34.
18. Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother 2005 54 : 611 22.
19. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 6 : 715 27.
20. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006 12 : 207 13.
21. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006 12 : 214 9.
22. Kaufman HL, DeRaffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005 115 : 1903 12.
23. Liu Y, Xia D, Li F, Zheng C, Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005 12 : 122 32.
24. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005 174 : 6013 22.
25. Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998 161 : 2187 94.
26. Blohm U, Roth E, Brommer K, Dumrese T, Rosenthal FM, Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002 169 : 5522 30.
27. Seliger B. Strategies of Tumor Evasion. Biodrugs 2005 19 : 347 54.
28. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8(+) T cells in patients with melanoma. J Immunol 2005 175 : 6169 76.
29. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004 228 : 130 7.
30. Peter I, Mezzacasa A, LeDonne P, Dummer R, Hemmi S. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res 2001 11 : 21 30.
31. Geertsen RC, Hofbauer GF, Yue FY, Manolio S, Burg G, Dummer R. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J Invest Derm 1998 111 : 497 502.
32. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006 119 : 254 64.
33. Frumento G, Piazza T, Di Carlo E, Ferrini S. Targeting Tumor-related Immunosuppression for Cancer Immunotherapy. Endocr Metab Immune Disord Drug Targets 2006 6 : 223 37.
34. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4(+) and CD8(+) regulatory T cells. J Immunol 2006 177 : 896 904.
35. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006 55 : 1185 97.
36. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006 66 : 5527 36.
37. Mantovani A, Ming WJ, Balotta C, Abdeljalil B, Bottazzi B. Origin and Regulation of Tumor-Associated Macrophages - the Role of Tumor-Derived Chemotactic Factor. Biochim Biophys Acta 1986 865 : 59 67.
38. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996 93 : 13119 24.
39. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004 200 : 1157 65.
40. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004 100 : 2281 91.
41. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001 31 : 1247 54.
42. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-yolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp.Med. 2000 192 : 303 10.
43. Wolf D, Rumpold H, Wolf AM. Regulatory T cells in cancer biology: a possible new target for biochemical therapies. Mini Rev in Med Chem 2006 6 : 509 13.
44. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+T cell immunity against a tumor/self-antigen is augmented by CD4(+) T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005 174 : 2591 601.
45. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003 9 : 606 12.
46. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4+CD25high Regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004 173 : 1444 53.
47. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4(+)CD25(+) regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004 34 : 336 44.
48. Chen ML, Pittett MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivoi. Proc Natl Acad Sci U S A 2005 102 : 419 24.
49. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006 176 : 1582 7.
50. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, et al. Tumor-derived CD4(+) CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007 56 : 48 59.
51. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting Edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006 177 : 40 4.
52. Chen W, Wahl SM. TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003 14 : 85 9.
53. Bacchetta R, Gregori S, Roncarolo MG. CD4+ regulatory T cells: Mechanisms of induction and effector function. Autoimmun Rev 2005 4 : 491 6.
54. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005 115 : 3623 33.
55. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005 106 : 2295 301.
56. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 6.
57. Peng G, Guo Z, Kiniwa Y, Voo Ks, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005 309 : 1380 4.
58. Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006 66 : 5427 35.
59. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004 101 : 4572 7.
60. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993 90 : 770 4.
61. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006 25 : 441 54.
62. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006 25 : 455 71.
63. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005 8 : 369 80.
64. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res 1999 59 : 1273 7.
65. Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, et al. Quantitative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998 77 : 7 12.
66. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996 66 : 607 10.
67. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small-cell lung-cancer cells express a type-2 cytokine pattern. Cancer Res 1995 55 : 3847 53.
68. Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung cancer-derived soluble mediators and prostaglandin E(2) enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996 157 : 5512 20.
69. Kim J, Modlin RL, Moy RL, Dubinett SM, Mchugh T, Nickoloff BJ, et al. Il-10 production in cutaneous basal and squamous-cell carcinomas. A mechanism for evading the local T cell immune-response. J Immunol 1995 155 : 2240 7.
70. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-1, HLA class-II and ICAM-1 molecules. Int J Cancer 1997 71 : 630 7.
71. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999 93 : 1634 42.
72. Ke Y, Kapp LM, Kapp JA. Inhibition of tumor rejection by [gamma][delta] T cells and IL-10. Cell Immunol 2003 221 : 107 14.
73. Garcia-Hernandez ML, Hernandez-Pando R, Gariglio P, Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002 105 : 231 43.
74. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003 9 : 1269 74.
75. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004 114 : 280 90.
76. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004 172 : 4100 10.
77. Cham CM, Gajewski TF. Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res 2005 31 : 107 18.
78. Fallarino I, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002 9 : 1069 77.
79. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006 176 : 6752 61.
80. Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res 2006 16 : 379 83.
81. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998 282 : 2263 6.
82. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 2006 231 : 247 56.
83. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001 194 : 823 32.
84. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 190 : 355 66.
85. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004 22 : 1700 8.
86. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004 34 : 613 22.
87. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP. Role of GITR in activation response of T lymphocytes. Blood 2002 100 : 350 2.
88. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4(+)CD25 (hi) T-regulatory cells. Blood 2006 108 : 253 61.
89. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells. J Immunol 2004 173 : 5008 20.
90. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005 202 : 885 91.
91. Calmels B, Paul S, Futin N, Ledoux C, Stoeckel F, Acres B. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 2005 12 : 198 205.
92. Soroosh P, Ine S, Sugamura K, Ishii N. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 2006 176 : 5975 87.
93. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005 105 : 2845 51.
94. Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A 2006 103 : 13138 43.
95. Ali SA, Ahmad M, Lynam J, Mclean CS, Entwisle C, Loudon P, et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 2004 22 : 3585 94.
96. Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 2004 64 : 3281 7.
97. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP. OX40 Ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol 2003 170 : 99 106.
98. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996 8 : 765 72.
99. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005 54 : 307 14.
100. Zha Y, Blank C, Gajewski TF. Negative regulation of T-Cell function by PD-1. Crit Rev Immunol 2004 24 : 229 37.
101. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000 192 : 1027 34.
102. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat Immunol 2001 2 : 261 8.
103. Petroff MG, Chen L, Phillips TA, Azzola D, Sedlmayr P, Hunt JS. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 2003 68 : 1496 504.
104. Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 2006 118 : 2657 64.